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Septic shock results from an uncontrolled inflammatory response, mediated primarily by LPS. Cholesterol transport plays
an important role in the host response to LPS, as LPS is neutralized by lipoproteins and adrenal cholesterol uptake is
required for antiinflammatory glucocorticoid synthesis. In this study, we show that scavenger receptor B-I (SR-BI), an HDL
receptor that mediates HDL cholesterol ester uptake into cells, is required for the normal antiinflammatory response to
LPS-induced endotoxic shock. Despite elevated plasma HDL levels, SR-BI–null mice displayed an uncontrollable
inflammatory cytokine response and a markedly higher lethality rate than control mice in response to LPS. In addition,
SR-BI–null mice showed a lack of inducible glucocorticoid synthesis in response to LPS, bacterial infection, stress, or
ACTH. Glucocorticoid insufficiency in SR-BI–null mice was due to primary adrenal malfunction resulting from deficient
cholesterol delivery from HDL. Furthermore, corticosterone supplementation decreased the sensitivity of SR-BI–null mice
to LPS. Plasma from control and SR-BI–null mice exhibited a similar ability to neutralize LPS, whereas SR-BI–null mice
showed decreased plasma clearance of LPS into the liver and hepatocytes compared with normal mice. We conclude
that SR-BI in mice is required for the antiinflammatory response to LPS-induced endotoxic shock, likely through its
essential role in facilitating glucocorticoid production and LPS hepatic clearance.
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Endotoxic shock remains a significant cause of death despite 
the use of various therapeutic approaches (1). LPS is the primary 
cause of Gram-negative sepsis. LPS, through its interaction with 
the LPS-binding protein–containing (LBP-containing) LBP-
CD14-TLR4 complex, activates macrophages, causing the release 
of inflammatory cytokines (2). While the inflammatory response 
represents a host defense to invading pathogens, uncontrolled 
systemic inflammation can lead to serious systemic complica-
tions such as disseminated intravascular coagulation, tissue dam-
age, and endotoxic shock (2).
LPS can be neutralized by the major lipoproteins, HDL, LDL, 
VLDL, and chylomicrons as well as apolipoproteins apoE and apoA-I 
(3–5). apoE may protect by redirecting LPS from Kupffer cells to 
hepatocytes (3). The preferential binding of LBP to HDL accounts 
for HDL being the primary carrier of LPS in the blood (6). While 
LPS is cleared mainly by hepatocytes, the mechanism or mecha-
nisms are unclear. Although scavenger receptor A (SR-A) has been 
reported to mediate LPS uptake and detoxification (7), SR-A–null 
mice showed unchanged production of TNF-α in response to LPS 
(8), casting doubt on the physiological role of SR-A in sepsis. These 
findings suggest the involvement of other scavenger receptors, such 
as scavenger receptor B-I (SR-BI), in LPS metabolism.
SR-BI is an HDL receptor that plays a key role in the reverse 
cholesterol transport pathway through mediating selective lipid 
uptake from HDL particles (9, 10). SR-BI in the liver is highly 
expressed in hepatocytes (9) and to a lesser extent in Kupffer cells 
(11) and functions to clear HDL cholesterol into the bile (12). 
Studies using SR-BI–deficient and –transgenic mice have shown 
that SR-BI is protective against atherosclerosis (10). SR-BI has a 
broad ligand-binding specificity and is involved in the binding and 
cellular uptake of various endogenous ligands, such as β-amyloid 
and serum amyloid A (13), apoptotic cells, and exogenous patho-
gens (10). For example, SR-BI plays a role as a receptor for hepa-
titis C virus and is required for virus infection (14). Importantly, 
SR-BI also mediates the binding and uptake of LPS (15), the major 
Gram-negative bacterial cell wall component, in macrophages and 
HeLa cells overexpressing SR-BI, and lipoteichoic acid (LTA) (16), 
a component of Gram-positive bacteria. Furthermore, SR-BI and 
its alternatively spliced variant, SR-BII (17), have been shown to 
directly bind a variety of bacteria with little discrimination, sug-
gesting a conserved role for these receptors in pattern recogni-
tion and innate immunity (18). This is supported by the fact that 
SR-BI–null mice are more susceptible to LPS-induced death, a 
finding attributed to a protective effect of SR-BI in inhibiting NO-
induced cell toxicity (19). A recent study, however, reported that 
SR-BI facilitates bacterial invasion and proliferation in cells, with 
evasion of lysosomal processing (16), indicating that SR-BI might 
facilitate bacterial infection and sepsis.
SR-BI is highly expressed in the adrenals, ovary, and testis, where 
it functions to provide cholesterol for steroid hormone synthesis 
through the selective cholesterol ester (CE) uptake from HDL and 
LDL (20–22). Although the LDL receptor (LDLR) also contributes 
Nonstandard	abbreviations	used: CE, cholesterol ester; Cyp11A1, cytochrome 
P450 side-chain cleavage enzyme; LAL, Limulus amebocyte lysate; LBP, LPS-binding 
protein; LDLR, LDL receptor; MCP-1, monocyte chemoattractant protein-1; Q-PCR, 
quantitative real-time PCR analysis; SR-A, scavenger receptor A; SR-BI, scavenger 
receptor B-I; StAR, steroidogenic acute regulatory protein.
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to cholesterol delivery through LDL uptake (23), SR-BI–mediated 
HDL cholesterol uptake appears to be the major source of choles-
terol for glucocorticoid synthesis in rodents (20, 24, 25). A criti-
cal role of SR-BI in humans is suggested by the observation that 
patients with familial hypercholesterolemia that lack functional 
LDLR show a normal response to ACTH (26). Glucocorticoids 
exert antiinflammatory effects by suppressing proinflammatory 
cytokines (e.g. TNF-α, IL-1, IL-6) and stimulating antiinflammato-
ry mediators (IL-10, TGF-β) (27). Adrenal deficiency, characterized 
by glucocorticoid insufficiency, is often associated with sepsis (28). 
Common causes of adrenal failure are impaired function of the 
upstream hypothalamic-pituitary-adrenal axis (secondary adre-
nal insufficiency) and malfunction or destruction of the adrenal 
glands (primary adrenal insufficiency). Since only small amounts 
of glucocorticoids are stored in the adrenals (29), primary adrenal 
failure in endotoxic shock is usually due to insufficient glucocor-
ticoid biosynthesis (29). Depletion of plasma HDL in apoA-I–null 
mice (30) or by inactivation of SR-BI (31) markedly reduces CE 
content in the adrenals. In the case of apoA-I–null mice, adrenal 
function was affected and corticosterone production was limited 
(30). In SR-BI–null mice, adrenal function appeared unaffected 
under normal physiological conditions (10).
In this study, we have investigated the role of SR-BI in regulat-
ing LPS-induced inflammation and endotoxic shock. Studies using 
control and SR-BI–null mice have shown that SR-BI expression is 
essential for stimulated glucocorticoid production in the adrenals 
in response to LPS and stress, and that glucocorticoid insufficiency 
as well as reduced LPS clearance likely contribute to the enhanced 
inflammation and endotoxin-induced death in SR-BI–null mice.
Results
SR-BI–null mice show an exaggerated inflammatory response to LPS-
induced endotoxic shock. To determine the influence of SR-BI on 
LPS-induced inflammation, SR-BI–null and control mice were 
injected i.p. with LPS (0.5 μg/g body weight), and serum cytokine 
levels were determined by ELISA at various times following injec-
tion. As shown in Figure 1, LPS resulted in a strong induction 
of both TNF-α and IL-6. In the case of TNF-α, maximum con-
centrations were reached by 2 hours and were markedly higher 
in the SR-BI–null mice than in control mice (Figure 1A). In the 
case of IL-6, LPS-induced plasma concentrations reached nearly 
similar maximal levels in both SR-BI–null and control mice after 
2 hours (Figure 1B). However, IL-6 levels in control mice returned 
to baseline levels after 8 hours, whereas the level of IL-6 in SR-BI– 
null mice remained elevated for 24 hours before dropping to base-
line levels by 48 hours. An increased TNF-α and IL-6 cytokine 
response in SR-BI–null mice compared with control mice was 
evident at each LPS concentration tested, and no cytokine induc-
tion was observed in mice injected with saline alone (data not 
shown). TNF-α and IL-6 expression in the livers of these mice were 
assessed by quantitative real-time PCR analysis (Q-PCR) of mRNA 
levels. In line with the observed differences in protein expression, 
SR-BI–null mice had higher expression of liver mRNA for both 
TNF-α and IL-6 in response to LPS than control mice (Figure 
1, C and D). However, the lack of close correlation between liver 
mRNA levels and plasma cytokine levels suggests posttranscrip-
tional regulation mechanisms and/or the contribution of nonhe-
patic cytokine production.
A cytokine array analysis of plasma at either 2 or 24 hours after 
LPS injection showed that the levels of a variety of proinflamma-
tory cytokines were increased to a significantly greater extent in 
SR-BI–null mice compared with control mice (Table 1). Cytokines 
that showed no difference between SR-BI–null and control mice 
at 2 hours are also listed in Table 1. Of these, IL-5, IL-6, and IL-10 
levels were significantly greater in SR-BI–null mice at 24 hours, 
whereas the remainder showed no difference at 24 hours (data not 
shown). Of all the cytokines assayed, IL-4, IL-7, IL-13, and IL-15 
did not show any response to LPS in either of the 2 genotypes. 
These are Th2 cytokines associated with allergy, autoimmune dis-
ease, and parasitic infection. Under basal conditions in the absence 
of LPS, no differences in cytokine levels were observed between 
SR-BI–null and control mice. These data clearly show that SR-BI–
null mice exhibit a markedly increased inflammatory response to 
LPS compared with control SR-BI+/+ mice.
An overproduction of proinflammatory cytokines caused by LPS 
in SR-BI–null mice suggests increased susceptibility to endotoxic 
shock and death in these animals. Consistent with this hypothesis, 
we observed a marked difference in survival rate of SR-BI–null and 
control mice injected i.p. with a single relatively moderate dose of 
LPS (5 μg/g body weight) (Figure 2). Neither the control group 
Figure 1
Hyperinflammatory response in SR-BI–/– mice challenged 
with LPS. SR-BI–/– and SR-BI+/+ mice were injected i.p. with 
0.5 μg/g body weight of LPS. Plasma TNF-α and IL-6 levels 
were determined by ELISA (A and B). Liver TNF-α and IL-6 
mRNA levels were determined by Q-PCR (C and D). Val-
ues shown are the mean ± SD (n = 3). Similar results were 
found in 4 independent experiments.
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nor the SR-BI heterozygous (+/–) group had any fatalities (n = 8), 
whereas there was a 100% fatality rate within 3 days in the SR-BI–
null group (n = 8). The SR-BI–null mice showed symptoms of stress, 
including reduced movement, shivering, and diarrhea, whereas 
both the control mice and heterozygous mice appeared free of 
these symptoms. As was the case for mice treated with 0.5 μg/g 
body weight of LPS (Figure 1 and Table 1), SR-BI–null mice treated 
with the higher dose of LPS (5 μg/g body weight) showed markedly 
enhanced plasma levels of TNF-α at 2 hours compared with the 
control mice, whereas IL-6 levels were induced to the same extent 
in the 2 mouse groups at the same time point (Figure 2B).
Glucocorticoid insufficiency in SR-BI–null mice during LPS-induced 
inflammation. Glucocorticoids play an important regulatory role in 
the inflammatory response, and since SR-BI–dependent uptake of 
cholesterol into the adrenal is thought to be important in provid-
ing cholesterol for glucocorticoid synthesis, we evaluated adrenal 
function in SR-BI–null mice during LPS-induced inflammation. 
As demonstrated in Figure 3A, plasma corticosterone levels in 
control mice were markedly increased (3- to 4-fold) in response to 
LPS in a dose-dependent manner. Mice lacking CD36 (CD36–/–), 
a class B scavenger receptor closely related to SR-BI but which 
does not mediate efficient CE uptake from HDL (32), showed a 
similar corticosterone response to controls. In SR-BI–null mice, 
however, plasma corticosterone levels were completely unaltered 
during LPS-induced inflammation, indicating adrenal glucocor-
ticoid insufficiency. A lack of corticosterone induction was also 
seen in SR-BI–null mice treated with the higher doses of LPS of 
5 μg/g body weight (plasma corticosterone levels [ng/ml]: SR-BI+/+, 
124.3 ± 25.5 vs. SR-BI+/+ plus LPS, 1012.7 ± 97, P < 0.05; SR-BI–/–, 
101 ± 40 vs. SR-BI–/– plus LPS, 118 ± 53.5, P > 0.05). To determine 
whether this glucocorticoid insufficiency directly contributes to 
the increased mortality observed in SR-BI–null mice challenged 
with LPS, we tested the effect of corticosterone supplementation 
through the drinking water on survival rates in mice challenged 
with LPS. In the case of control mice, no deaths were observed in 
either the corticosterone-treated or untreated groups (Figure 3B). 
However, corticosterone supplementation through the drinking 
water markedly improved the survival rate in SR-BI–null mice, 
albeit not to the 100% survival rate seen in the control groups. 
Corticosterone supplementation significantly increased plasma 
corticosterone levels in SR-BI–null mice such that levels measured 
in surviving SR-BI–null mice and control mice were similar at 66 
hours and exceeded those in unsupplemented control mice (Figure 
3C). Supplementation with corticosterone also markedly reduced 
LPS-induced TNF-α levels in both SR-BI–null and control mice 
treated with LPS at either a low (0.5 μg/g body weight) or higher 
dose (5 μg/g body weight), although in supplemented SR-BI–null 
mice at the high LPS dose, TNF-α levels remained at higher levels 
than in control mice (Figure 3D). Corticosterone did not simply 
delay the onset of septic shock, since the surviving mice appeared 
to be recovering from LPS treatment judged on the basis of the 
physical signs, which included improved activity, normal breath-
ing, and lack of shivering. In addition, in surviving mice, the levels 
of TNF-α and IL-6 were reduced to baseline or near baseline levels 
(less than 1 ng/ml) at the end of the experiments.
To determine whether the lack of glucocorticoid response in SR-BI– 
null mice is due to altered ACTH production by the pituitary or to 
a more direct effect at the level of the adrenal, we first compared 
plasma ACTH levels in both LPS-treated and control mice. ACTH 
levels in SR-BI–null mice and control mice were similar under basal 
conditions and increased significantly in response to LPS (Figure 
4A). To investigate whether the decreased corticosterone level in 
the SR-BI–null mice was due to decreased responsiveness of the 
adrenal to ACTH stimulation, mice were injected s.c. with ACTH 
(Figure 4B). A maximal corticosterone level in control mice was 
achieved at a dose of 1 unit of ACTH, and no further increase was 
seen with doses up to 8 units of ACTH (data not shown). SR-BI– 
null mice, unlike control mice, failed to respond to ACTH over a 
5-hour period following injection with 2 units of ACTH (Figure 
4B) or 4 units of ACTH (data not shown). Interestingly, insuffi-
cient corticosterone production was not only found in the inflam-
Table 1
Cytokine levels in SR-BI+/+ and SR-BI–/– mice in response to LPS
Cytokine  SR-BI+/+ SR-BI–/– SR-BI+/+/LPS SR-BI–/–/LPS 
(pg/ml) 
Cytokines showing differences between SR-BI–/– and SR-BI+/+ mice
Two hours after LPS injection
GM-CSF 17 ± 14 13 ± 10 146 ± 22 332 ± 120A
IL-1β <3.2 <3.2 17 ± 4.5 47 ± 12A
IL-9 12 ± 10 16 ± 13 28 ± 8.0 47 ± 12A
IL-12 40 ± 35 20 ±10 80 ± 14 115 ± 5.0A
MIP 32 ± 31 30 ± 27 4778 ± 267 8439 ± 270A
RANTES 5.9 ± 4.0 5.2 ± 2.0 70 ± 33 397 ± 186B
TNF-α <3.2 <3.2 248 ± 50 864 ± 385B
Twenty-four hours after LPS injection
IL-5 4.3 ± 1.6 4.0 ± 1.0 20 ± 26 171 ± 76B
IL-6 14 ± 8.0 10 ± 4.5 375 ± 127 8432 ± 2716B
IL-10 <3.2 <3.2 17 ± 0.7 225 ± 88B
KC 39 ± 11 28 ± 7.6 183 ± 68 6063 ± 3937A
MCP-1 18 ± 16 14 ± 18 471 ± 206 4744 ± 798B
Cytokines not showing difference between SR-BI–/– and SR-BI+/+ mice
Two hours after LPS injection
IFN-γ <3.2 <3.2 18.4 ± 5.4 14.9 ± 16.8
IL-1α 16 ± 5 7.1 ± 5.2 443 ± 84 302 ± 126
IL-2 <3.2 <3.2 6.2 ± 1.9 8.2 ± 5.9
IL-4 <3.2 <3.2 <3.2 <3.2
IL-5 4.0 ± 1.0 5.3 ± 1.6 14.2 ± 6.4 2.5 ± 2.3
IL-6 26 ± 12 14 ± 6 >10000 >10000
IL-7 <3.2 <3.2 <3.2 <3.2
IL-10 <3.2 <3.2 654 ± 385 541 ± 96
IL-13 110 ± 94 129 ± 80 242 ± 85 252 ± 50
IL-15 43 ± 38 36 ± 31 49 ± 11 45 ± 8
IL-17 9.1 ± 5.3 4.4 ± 1.7 16.5 ± 0.6 30 ± 14
IP-10 183 ± 96 183 ± 77 1441 ± 435 1337 ± 662
SR-BI–/– and SR-BI+/+ mice were injected i.p. with saline or 0.5 μg/g body 
weight LPS (SR-BI+/+/LPS and SR-BI–/–/LPS). Mice were sacrificed after 
2 or 24 hours (as indicated). Serum was analyzed by cytokine protein 
array (multiplex biomarker assay using xMAP technology). In the case 
of 4 cytokines, IL-6, MCP-1, G-CSF, and keratinocyte derived chemo-
kine (KC), measured on the same array, levels were markedly induced 
by LPS treatment and at 2 hours exceeded 10,000 pg/ml and were not 
quantifiable. IL-6 was not significantly different between the 2 groups as 
shown by ELISA in Figure 1. MCP-1 at 2 hours was significantly different 
between the 2 groups when treated with a lower dose of LPS (0.125 μg/g 
body weight) as shown by ELISA in Figure 6. KC was significantly greater 
at 24 hours in SR-BI–null mice than in control mice (Table 1A). Values 
shown are the mean ± SD (n = 3). AP < 0.05; BP < 0.01, SR-BI+/+/LPS vs. 
SR-BI–/–/LPS. Similar results were found in 2 independent experiments. 
IP-10, interferon-inducible protein 10.
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matory response but also resulted from the stress of a 5°C swim 
(Figure 4C). These experiments indicate that adrenal insufficiency 
occurred not only under severe acute phase response conditions 
but also following a common physical/mental stress challenge.
To relate our findings on the response of SR-BI–null and control 
mice to bacterial infection, we assessed the inflammatory response 
and adrenal function in SR-BI–null mice challenged with Gram-
negative bacteria Escherichia coli. As shown in Figure 5, 2 hours fol-
lowing an E. coli challenge, plasma levels of TNF-α and monocyte 
chemoattractant protein-1 (MCP-1) were each significantly elevat-
ed in SR-BI–null mice compared with the control mice (Figure 5A). 
At the same time, plasma corticosterone levels were markedly lower 
following E. coli exposure in SR-BI–null mice than in control mice 
(Figure 5B). Cytokine levels and plasma corticosterone levels were 
similarly low in untreated SR-BI–null and control mice (data not 
shown). These results clearly indicate that SR-BI deficiency results 
in an increased inflammatory response following E. coli infection.
Adrenal insufficiency contributes to an enhanced inflammatory 
response and endotoxic shock in SR-BI–null mice. To further investi-
gate the role of the adrenals in the LPS-induced inflammatory 
response, both control and SR-BI–null mice were adrenalecto-
mized and then treated 7 days after recovery with LPS. It should 
be noted that adrenalectomy renders mice deficient, not only in 
corticosterone, but also in other adrenal hormones that may each 
have a role in inflammation (33). LPS was used at a relatively low 
dose (0.125 μg/g body weight) since adrenalectomy increases sen-
sitivity in mice to inflammation (34). Prior to LPS injection, basal 
levels of both TNF-α and MCP-1 were similarly low in control and 
SR-BI–null mice (data not shown). In the sham-operated SR-BI– 
null mice, there was an inflammatory response to LPS such that 
the levels of TNF-α, IL-6, and MCP-1 were markedly greater than 
the corresponding levels in control SR-BI+/+ mice 2 hours fol-
lowing LPS injection (Figure 6, A–C). A greater inflammatory 
response to LPS was observed in the adrenalectomized mice from 
both groups. In the case of TNF-α, levels were approximately 38% 
higher (P < 0.05) in the adrenalectomized SR-BI–null mice than 
in control mice (Figure 6A). However, no differences in either IL-6 
or MCP-1 levels were observed between adrenalectomized SR-BI– 
null and control mice under conditions in which the levels of the 
2 cytokines were both extremely high (Figure 6, B and C). The 
differences observed in IL-6 and MCP-1 levels between sham-
operated control and SR-BI–null mice treated with LPS were not 
observed in the experiments shown in Figure 1B and Table 1. 
This difference is likely related to the lower dose of LPS used in 
the experiment shown in Figure 6. Thus, while cytokine levels in 
Figure 2
SR-BI–/– mice are more sensitive to LPS-induced lethality. (A) Survival 
of SR-BI–/– mice in response to LPS. SR-BI–/–, SR-BI+/–, and SR-BI+/+ 
mice (n = 8) were injected i.p. with 5 μg/g body weight of LPS. Mice 
were carefully monitored, and survival rates at the indicated times 
were recorded (SR-BI–/– vs. SR-BI+/+; P < 0.001). (B) Plasma cytokine 
levels in SR-BI–/– and SR-BI+/+ mice challenged with LPS. LPS (5 μg/g 
body weight) was injected i.p. into SR-BI+/+ and SR-BI–/– mice, and 
blood was collected 2 hours following LPS injection. Plasma IL-6 and 
TNF-α levels were determined by ELISA. Values shown are the mean 
± SD (n = 4) (*P < 0.05; **P < 0.01). Similar results were seen in 3 
independent experiments.
Figure 3
Plasma corticosterone levels are not induced in SR-BI–/– 
mice challenged with LPS. (A) Corticosterone levels in 
SR-BI–/– and CD36–/– mice injected with various amounts 
of LPS (0.17, 0.5, and 1.5 μg/g body weight) and sac-
rificed 2 hours later. Values shown are the mean ± SD 
(n = 4). a, b, c, P < 0.05. (B) SR-BI–/– and SR-BI+/+ mice 
were given corticosterone (100 μg/ml in 0.1% ethanol) in 
drinking water (SR-BI–/–/C, SR-BI+/+/C) or 0.1% ethanol 
only 8 hours prior to i.p. injection of LPS (5 μg/g body 
weight). Survival rates at the indicated times following 
LPS administration are shown (n = 7). (C) Plasma cor-
ticosterone levels in the surviving mice. Surviving mice 
were sacrificed 66 hours after LPS challenge. Values 
shown are the mean ± SD (n = 4 for SR-BI–/–; n = 7 for 
SR-BI+/+). (D) Plasma TNF-α levels 2 hours after LPS 
injection with or without corticosterone supplementation. 
SR-BI+/+ and SR-BI–/– mice were injected i.p. with 0.5 and 
5 μg/g body weight of LPS. Values shown are the mean 
± SD (n = 4). *P < 0.05; **P < 0.01. Similar results were 
found in 3 independent experiments.
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SR-BI–null mice reached similar and possibly maximal levels at 
the 2 LPS doses used, the responses of IL-6 and MCP-1 in control 
mice were much lower at the lower LPS dose. These results are in 
line with an enhanced sensitivity of SR-BI–null mice to low doses 
of LPS. Overall, the results of this experiment show that adrenal-
ectomy to a large extent abolished the differences in inflamma-
tory cytokines between SR-BI–null and control mice.
LPS-treated adrenalectomized mice of both control and SR-BI– 
null groups showed low levels of plasma corticosterone that were 
similar to the levels in untreated SR-BI–null mice (Figure 6D). 
These data further confirm the finding that a lack of SR-BI pre-
vents LPS-induced production of corticosterone in adrenals. In 
adrenalectomized mice, the levels of corticosterone were low but 
significant and were higher in control than in SR-BI–null mice. 
Extra-adrenal glucocorticoid synthesis has been reported (33), and 
our results point to the possibility that such extra-adrenal synthe-
sis may also be dependent on SR-BI. Together, these data suggest 
that adrenal insufficiency plays a major role in contributing to 
the enhanced LPS-induced inflammatory response in SR-BI–null 
mice. At the same time, the significant difference between TNF-α 
levels in adrenalectomized SR-BI–null and control mice supports a 
conclusion that SR-BI influences inflammation by mechanisms in 
addition to its role on adrenal glucocorticoid production.
To address the possible mechanisms for adrenal insufficiency in 
SR-BI–null mice, we first examined ERK phosphorylation, a key 
step in the ACTH-induced signaling pathway in the adrenals (35). 
ERK phosphorylation to p-ERK was found to be induced by LPS 
within 1 hour in adrenals to a similar extent in SR-BI–null mice 
and control mice, with no significant changes in the levels of total 
ERK during the same period (data not shown). This result is consis-
tent with ACTH signaling in the adrenals being initiated in a nor-
mal manner by ACTH in SR-BI–null mice. Two key enzymes in the 
biosynthesis of glucocorticoids that are transcriptionally induced 
during stimulation of corticosterone production from cholesterol 
are steroidogenic acute regulatory protein (StAR) and cytochrome 
P450 side-chain cleavage enzyme (Cyp11A1) (29). StAR is required 
for cholesterol transport across the inner mitochondrial mem-
brane, and Cyp11A1 converts cholesterol into pregnenolone by 
catalyzing cholesterol side-chain cleavage. In untreated mice, the 
expression of both StAR and Cyp11A1 mRNA in adrenals was sim-
ilar in SR-BI–null and control mice, as assessed by adrenal mRNA 
levels (Figure 7, A and B). Expression of mRNA for both proteins 
was upregulated by LPS within 1 hour in control mice and to at 
least the same extent in SR-BI–null mice. mRNA levels for both 
proteins remained higher in SR-BI–null mice compared with con-
trol mice for at least 24 hours. In line with StAR transcriptional 
Figure 4
Primary adrenal deficiency in SR-BI–/– mice. (A) Plasma ACTH levels 
in SR-BI+/+ and SR-BI–/– male mice challenged with LPS (0.5 μg/g body 
weight of LPS or saline) for 2 hours (B) ACTH-induced corticosterone 
response in SR-BI+/+ and SR-BI–/– mice. Male SR-BI+/+ and SR-BI–/– 
mice were injected with 2 U of ACTH s.c. and sacrificed under anes-
thesia at the indicated times. (C) Adrenal insufficiency in SR-BI–/– mice 
under stress. Female SR-BI+/+ and SR-BI–/– mice were stressed by a 
3-minute cold water (5°C) swim followed by a 17-minute rest at room 
temperature. Values shown are mean ± SD (n = 4). Similar results 
were found in 3 independent experiments. *P < 0.05; **P < 0.01.
Figure 5
Hyperinflammatory response in SR-BI–/– mice challenged with E. coli. 
SR-BI–/– and SR-BI+/+ mice were injected i.p. with 2 × 107 CFU E. coli 
per mouse. Two hours after the injection, mice were sacrificed and 
plasma was collected. (A) Plasma cytokine levels determined by 
ELISA. (B) Plasma corticosterone levels determined by RIA. Values 
shown are mean ± SD (n = 4). Similar results were found in 2 indepen-
dent experiments. *P < 0.05; **P < 0.01.
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upregulation, the levels of StAR protein in the adrenals were also 
upregulated in both groups of mice and at least to the same extent 
in SR-BI–null mice as in control mice (Figure 7C). These results 
again suggest normal adrenal regulatory responses in respect to 
ACTH signaling in SR-BI–null mice.
The availability of unesterified cellular cholesterol is a key deter-
minant in corticosterone production (29). To assess whether the 
inability of SR-BI–null mice to induce corticosterone synthesis in 
SR-BI–null mice results from limited cholesterol availability in 
the adrenal, we analyzed the expression of 2 proteins, the LDLR 
and HMG-CoA reductase, whose expression at the transcriptional 
level is highly regulated by the level of intracellular cholesterol 
(25, 36). The LDLR serves to internalize LDL, and HMG-CoA 
reductase is the key regulatory enzyme in cholesterol biosynthesis. 
Adrenal mRNA levels for the 2 proteins were determined in con-
trol and SR-BI–null mice before and after LPS treatment (Figure 
7, D and E). Basal LDLR mRNA levels were about 2-fold greater 
in SR-BI–null than in control mice, indicative of decreased cellu-
lar cholesterol levels in SR-BI–null mice, as previously reported by 
others (31) (Figure 7D). In the case of control mice, mRNA lev-
els for LDLR were moderately increased (<2 fold) following LPS 
treatment and returned to unstimulated levels within 24 hours. 
In contrast, LPS induced a striking increase in LDLR mRNA levels 
in SR-BI–null mice to levels that were about 4- to 5-fold higher 
than those in control mice. Similarly, HMG-CoA reductase was 
markedly upregulated (about 7-fold) in SR-BI–null mice but was 
relatively unchanged in control mice following LPS treatment 
(Figure 7E). The extensive transcriptional upregulation of these 
Figure 6
Effects of adrenalectomy on LPS-induced 
response in SR-BI–/– and SR-BI+/+ mice. 
Mice were adrenalectomized and allowed to 
recover for 1 week. Adrenalectomized mice 
(ADX) and sham-operated mice (sham) 
were injected i.p. with LPS (0.125 μg/g body 
weight), and 2 hours later, plasma cytokines 
and corticosterone levels were determined. 
(A) Plasma TNF-α levels. (B) Plasma IL-6 
levels. (C) Plasma MCP-1 levels. (D) Plas-
ma corticosterone levels. Values shown are 
mean ± SD (n = 5). *P < 0.05; **P < 0.01. 
Similar results were found in 3 independent 
experiments.
Figure 7
Adrenal gene expression during LPS-induced inflammatory response. SR-BI+/+ and SR-BI–/– mice were injected i.p. with 0.5 μg/g body weight of 
LPS. Mice were sacrificed at indicated time points, and adrenals were collected for mRNA extraction and Q-PCR. (A) Adrenal StAR mRNA. (B) 
Adrenal Cyp11A1 mRNA. (C) Adrenal StAR Western blot (10 μg cell protein/lane). Mice were sacrificed 2 hours after LPS injection. Adrenals 
were collected, and proteins were extracted. (D) Adrenal LDLR mRNA. (E) Adrenal HMG-CoA reductase mRNA. Values shown are mean ± SD 
(n = 3) of the ratio of genes for the target genes to that of the 18S rRNA. Similar results were found in 2 independent experiments.
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2 proteins by LPS in SR-BI–null mice indicates that, following 
LPS treatment, there is a rapid and marked decrease in cellular 
unesterified cholesterol, presumably due to an inability of cells to 
replenish intracellular cholesterol from circulating lipoproteins, 
intracellular biosynthesis, or cellular CE stores. Recent studies 
suggest that the cholesterol transporter ABCA1 may also contrib-
ute to adrenal cholesterol regulation (37). We evaluated adrenal 
ABCA1 expression in mice in response to LPS and found that both 
ABCA1 mRNA and protein levels were significantly lower in SR-BI– 
null mice, suggesting that ABCA1 did not contribute to low cel-
lular cholesterol levels in these mice (data not shown).
We conclude from these results that SR-BI in the adrenals is 
required to provide, through the process of selective CE uptake, 
sufficient cholesterol for glucocorticoid production under condi-
tions of high adrenal stimulation by ACTH, such as occurs during 
LPS-induced inflammation.
SR-BI plays a role in LPS clearance into hepatocytes. Since LPS is cleared 
largely via hepatocytes (8), which express high levels of SR-BI, 
and since SR-BI functions as a receptor for both HDL and LPS, 
we investigated whether SR-BI is responsible for LPS clearance by 
the liver. Cultured primary hepatocytes were isolated from control 
and SR-BI–null mice and assayed for their ability to take up LPS. 
As shown in Figure 8A, fluorescently labeled Alexa Fluor–LPS was 
taken up rapidly within 1 hour into control hepatocytes but to a 
significantly lesser extent in SR-BI–null hepatocytes. Similarly, cell 
association of 125I-LPS was decreased in SR-BI–null hepatocytes 
(Figure 8B). Interestingly, SR-BI can mediate 125I-LPS uptake 
more efficiently when LPS is in its HDL-associated form. While 
the uptake of LPS is reduced in SR-BI–null hepatocytes, a signifi-
cant level of SR-BI–independent uptake was observed, suggesting 
the involvement of other candidate receptors, such as SR-A, in 
this process. The clearance of 125I-LPS from plasma and its uptake 
into the liver was also investigated in control and SR-BI–null mice. 
First, the uptake of 125I-LPS into hepatocytes and nonhepatocytes 
isolated from livers collected 2 hours after LPS injection was mea-
sured. In line with the uptake of Alexa Fluor–LPS in cultured 
hepatocytes (Figure 8A), uptake of 125I-LPS was significantly lower 
(by approximately 50%) in the hepatocytes, but not nonhepato-
cytes, of SR-BI–null mice compared with control mice (Figure 9A). 
Thirty minutes following injection, 125I-LPS uptake into the liver 
of SR-BI–null mice was significantly lower (by approximately 40%) 
than in control mice (Figure 9B). In contrast, uptake of 125I-LPS 
into the spleen and kidney was similar in the 2 animal groups (Fig-
ure 9B). In line with the reduced uptake of 125I-LPS into the liver 
of SR-BI–null mice, 125I-LPS remaining in plasma was greater in 
SR-BI–null mice. We conclude from these results that hepatic 
SR-BI expressed in hepatocytes plays a major physiologically sig-
nificant role in clearance of LPS from plasma.
To assess whether the observed differences between control and 
SR-BI–null mice in response to LPS might be related to previously 
Figure 8
SR-BI–dependent uptake of LPS in hepatocytes. (A) Primary 
hepatocytes were washed and incubated with 5 μg/ml of Alexa 
Fluor–LPS at 37°C for 1 hour in DMEM medium containing 0.5% BSA. 
Fluorescence microscopy was performed at ×40 original magnifica-
tion with equal exposures (Alexa Fluor–LPS, red; DAPI, blue, nucle-
ar stain). (B) Association of lipid-free and HDL-bound 125I-LPS with 
SR-BI+/+ and SR-BI–/– primary hepatocytes. Where indicated (LPS + 
HDL), 125I-LPS (5 μg) was preincubated with human HDL3 (10 μg) at 
room temperature for 30 minutes before addition to cells. Hepatocytes 
were incubated with 5 μg/ml 125I-LPS or 125I-LPS + HDL at 37°C for 
1 hour in DMEM medium containing 0.5% BSA. Values shown are the 
mean ± SD of triplicate determinations (*P < 0.05). Similar results were 
found in 4 independent experiments.
Figure 9
LPS distribution in the liver. (A) LPS distribution in hepatocytes and 
nonhepatocytes. 125I-LPS (0.125 μg/g body weight) was injected 
through the tail vein into SR-BI–/– and SR-BI+/+ mice. After 2 hours, 
mice were sacrificed and hepatocytes and nonhepatocytes were isolat-
ed. (B) LPS tissue distribution. 125I-LPS (0.125 μg/g body weight) was 
injected through the tail vein into SR-BI–/– and SR-BI+/+ mice. Plasma, 
liver, kidney, and spleen were collected after 30 minutes. LPS distri-
bution was calculated as percentage of the total injected LPS dose. 
Values shown are the mean ± SD (n = 4). *P < 0.05. Similar results 
were found in 3 independent experiments.
research article
	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 118	 	 	 Number 1	 	 	 January 2008 371
described differences in HDL levels or HDL structure or composi-
tion in the 2 mouse strains, we analyzed plasma lipoprotein pro-
files in mice before and after LPS treatment. As previously report-
ed, plasma HDL cholesterol levels were elevated more than 2-fold 
in SR-BI–null mice compared with control mice (38), and the HDL 
particles in SR-BI–null mice were abnormally large and contained 
a higher content of free cholesterol (31) (data not shown). An LPS 
challenge lowered HDL cholesterol levels in both SR-BI–null mice 
and the control mice: SR-BI–/– basal, 220.6 ± 4.8 μg/dl, vs. SR-BI–/– 
plus LPS, 158.5 ± 14.5 μg/dl (P < 0.05); SR-BI+/+ basal, 79.1 ± 8.3 μg/dl, 
vs. SR-BI+/+ plus LPS, 57.3 ± 8.1 mg/dl (P < 0.05). Free cholesterol was 
also decreased to a similar extent between the 2 mouse strains: SR-BI–/– 
basal, 86.9 ± 4.36 μg/dl, vs. SR-BI–/– plus LPS, 69.2 ± 3.92 μg/dl 
(P < 0.05); SR-BI+/+ basal, 24.5 ± 1.89 μg/dl, vs. SR-BI+/+ plus LPS, 
17.9 ± 0.57 μg/dl (P < 0.05). A Limulus amebocyte lysate (LAL) 
assay was used to measure the neutralizing effect of lipoprotein 
from SR-BI–null mice and control mice. No difference in plasma 
LPS neutralization was found between the 2 genotypes (Figure 10). 
This indicates that HDL from SR-BI–null mice, like control mice, 
is able to bind and neutralize LPS effectively.
Discussion
The present study demonstrates that SR-BI–null mice exhibit 
an enhanced inflammatory response to LPS as shown by highly 
elevated levels of inflammatory cytokines compared with control 
mice and decreased survival when challenged with endotoxin. This 
occurs despite the elevated levels of HDL in these mice, which is 
normally protective against LPS-induced inflammation. Strik-
ingly, SR-BI–null mice failed to show any significant induction of 
corticosterone production in response to LPS. A lack of glucocor-
ticoid stimulation was also observed in these mice in response to 
exogenous ACTH, indicating that the glucocorticoid insufficiency 
is not due to impaired signaling in the hypothalamic-pituitary-
adrenal axis upstream of the adrenals but rather is the result of pri-
mary adrenal deficiency due to an inadequate cholesterol supply. 
In addition to its role in glucocorticoid production, our results 
show that SR-BI also plays a role in the clearance of plasma LPS.
Our findings that corticosterone supplementation in SR-BI–null 
mice exerts a major protective effect against endotoxin-induced 
death provides strong support for a key protective role for glu-
cocorticoids in endotoxin-induced death. Glucocorticoids act to 
efficiently limit the inflammatory response (39), and stimulation 
of glucocorticoid production by the adrenals has generally been 
considered a key component in host defense against severe inflam-
mation and endotoxic shock (27). Our results further point to the 
strong possibility that SR-BI protects against endotoxemia in part 
through its role in glucocorticoid biosynthesis. However, since 
pharmacological doses of glucocorticoids have been shown to be 
protective even in the absence of adrenal insufficiency (28), it is 
possible that glucocorticoid supplementation at the relatively high 
levels reached in the SR-BI–null mice protects against endotoxemia 
in a manner unrelated to the adrenal insufficiency present in these 
mice. Since endotoxic shock is often associated with low levels of 
glucocorticoids, glucocorticoids have long been used in the man-
agement of sepsis and shown to efficiently limit uncontrollable 
inflammation (1). However, the concept of adrenal deficiency dur-
ing sepsis is complex and is still in some doubt (28). Clinical trials, 
for example, have not shown survival benefit with the early use of 
high-dose corticosteroids in adrenally intact patients with severe 
sepsis (1). On the other hand, survival benefit was seen in a group 
of adrenally insufficient patients that did not respond to a corti-
cotropin-stimulation test (28), and further clinical studies on the 
role of glucocorticoids in sepsis are therefore required.
During the acute phase of inflammatory response, the increased 
secretion of corticosterone depends on increased synthesis, a 
complex process involving a number of key regulatory steps. Our 
results show a normal increase in ACTH levels in SR-BI–null mice in 
response to LPS as well as a typical adrenal response to ACTH. Thus, 
LPS induced plasma levels of ACTH similar to those in control mice 
and also triggered typical ERK phosphorylation in the adrenals. Two 
other key regulatory proteins were shown to respond to stimulation 
of SR-BI–null mice similarly to control mice. StAR, which is required 
for cholesterol transport to the inner leaflet of mitochondria (29), 
and Cyp11A1, the side-chain cleavage enzyme responsible for preg-
nenolone formation (29), are both upregulated in adrenals in SR-BI– 
null mice as in control mice. Together, our data indicate normal 
ACTH release and consequent signaling in the adrenals in response 
to LPS and point to insufficient uptake of cholesterol required for 
glucocorticoid synthesis in SR-BI–null mice.
Corticosterone synthesis is dependent on an adequate supply of 
cholesterol to the adrenal cortex zona fasciculata cells. Cholesterol 
for steroid synthesis is derived largely from plasma lipoproteins in 
animals as well as humans (25, 40). Previous studies have shown 
that cholesterol can be taken up from HDL by SR-BI in the form 
of esterified and free cholesterol, although CEs likely contribute 
to the majority of uptake (20, 41, 42). Cholesterol is also taken up 
from LDL by both the LDLR (23) and SR-BI (22, 43). However, HDL 
appears to be the more important source of cholesterol (24, 30). 
Consequently, apoA-I–null mice with low plasma HDL fail to accu-
mulate CE in the adrenals and were shown to have a reduced glu-
cocorticoid response to a swim stress test or ACTH challenge (30). 
Although SR-BI–null mice were found to have no gross phenotypic 
alterations, it was not clear whether these animals had an altered 
steroidogenic response (10). Our results show that during severe 
stress such as occurs in the response to LPS, SR-BI is absolutely 
required for enhanced corticosterone synthesis. Moreover, in addi-
tion to its role in the response to bacterial LPS, SR-BI was shown to 
be required for a normal glucocorticoid response to the conditions 
of a swim stress test. Thus, the critical role of SR-BI is not limited 
Figure 10
Plasma from SR-BI+/+ and SR-BI–/– mice showed similar LPS neutral-
ization activity. Plasma (1 μl) from SR-BI+/+ and SR-BI–/– mice (pooled 
from 4 mice in each group) was incubated with different amounts of 
LPS (10 ng, 25 ng, 50 ng, and 100 ng) at 37°C for 1 hour. Endotoxin 
activities relative to no-plasma controls at each LPS concentration 
(percentage of neutralization) were determined by using a commer-
cially available LAL assay kit. Similar results were found in 3 indepen-
dent experiments.
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to the response of the foreign inflammatory agent LPS but is also 
important in the glucocorticoid response to physical and mental 
stress unrelated to bacterial infection.
The cholesterol supply in adrenals is potentially derived from 3 
main sources, namely (a) CE from circulating HDL or LDL, (b) CE 
from CE droplets present in cells, and (c) endogenous cholesterol 
synthesis. While cholesterol synthesis may provide sufficient cho-
lesterol for basal corticosterone synthesis, our results in SR-BI–null 
mice show that, under conditions of high demand, endogenous 
synthesis is unable to support increased corticosterone production. 
This occurs despite a marked induction of HMG-CoA reductase, 
the key regulatory enzyme in cholesterol biosynthesis. Similarly, 
despite its marked upregulation, the LDLR was also unable to sup-
port enhanced corticosterone production in these mice. This is in 
line with earlier findings that corticosterone production in LDLR-
null mice is unimpaired (25). Our results clearly demonstrate that 
SR-BI–mediated selective CE uptake is essential for enhanced corti-
costerone production. The CE taken up by SR-BI serves as a source 
of cholesterol in CE droplets found in adrenocortical cells, as previ-
ously shown by the reduced cellular CE content in apoA-I–null and 
also SR-BI–null mice (10, 30). Such droplets are considered to be 
short-term stores of cholesterol for glucocorticoid synthesis, since 
they are rapidly depleted under ACTH stimulation (40). CE taken 
up by SR-BI may also be used more directly for glucocorticoid syn-
thesis following its uptake and rapid hydrolysis by hormone-sen-
sitive lipase (41). Hormone-sensitive lipase plays a key role in the 
hydrolysis of CE delivered to cells by SR-BI as well as CE stored in 
CE droplets (25). Although the SR-BI–null mice used in this study 
lack both SR-BI and SR-BII isoforms, SR-BI likely contributes to 
the vast majority of CE uptake, since SR-BII is expressed at low lev-
els in the adrenals compared with SR-BI and is also less active in 
cholesterol uptake than SR-BI (17).
The critical role of SR-BI in glucocorticoid production suggests 
that downregulation of SR-BI–mediated HDL cholesterol delivery 
to the adrenals may be a mechanism contributing to glucocorti-
coid insufficiency, which is often observed during sepsis. During 
the inflammatory response to endotoxin, SR-BI has been shown 
to be downregulated in hepatocytes (44) and macrophages (45). 
Although the effect of LPS on SR-BI regula-
tion in the adrenals is not known, downregu-
lation of SR-BI would reduce cholesterol sup-
ply to the adrenal and may lead to decreased 
glucocorticoid production. Furthermore, the 
inflammatory response is typically character-
ized by a relatively rapid reduction in plasma 
levels of HDL cholesterol and apoA-I (46). 
Although the mechanisms responsible for 
this rapid decline in HDL remain uncertain, 
reduced HDL levels would also be expected 
to decrease SR-BI–mediated HDL cholesterol 
delivery to the adrenals. The combined effects 
of reduced HDL and SR-BI during inflamma-
tion may thus lead to significant reductions in 
glucocorticoid production.
Our finding that corticosterone supplemen-
tation did not completely normalize endotox-
in-induced death in SR-BI–null mice, together 
with the fact that adrenalectomy did not com-
pletely abolish the difference in TNF-α response 
between SR-BI–null and control mice, indicates 
that SR-BI exerts other nonadrenal protective functions. SR-BI–null 
mice have abnormally large cholesterol-rich HDL particles due to 
defective HDL CE clearance (31). The apoA-I levels in normal and 
SR-BI–null mice are similar, suggesting that the number of HDL 
particles in the 2 mouse strains are also similar. Since lipoproteins 
such as LDL (5) and HDL (47) have strongly protective effects 
through their ability to neutralize LPS, we investigated whether an 
enhanced susceptibility of SR-BI–null mice to LPS might be due to 
an inability of the abnormal HDL in these mice to neutralize LPS. 
Our results, however, showed that the total LPS neutralizing activ-
ity of plasma from SR-BI–null and control mice was similar, thus 
showing effective binding and neutralization in both cases.
Earlier studies have shown that LPS, either in lipid-free form or 
when associated with HDL, is bound and internalized by SR-BI in 
HeLa cells and macrophages (15). On this basis, SR-BI might facili-
tate LPS clearance into hepatocytes, thereby decreasing the LPS 
burden. Our findings demonstrate that SR-BI indeed contributes 
significantly to LPS uptake into hepatocytes and to LPS clearance 
into the liver. In the case of nonhepatocytes, no significant differ-
ence was found in LPS association between control cells and SR-BI– 
null cells. Although earlier studies have pointed to the ability of 
Kupffer cells to take up and detoxify LPS, the mechanisms for this 
are ill-defined (8). However, our results suggest that the stimula-
tion of inflammatory cytokines by LPS in Kupffer cells does not 
depend on the ability of SR-BI to bind or internalize LPS, as has 
been reported in the case of the THP-1, a human monocyte cell 
line (48). Thus, while SR-BI may serve other protective and antiin-
flammatory functions, these occur within the context of a power-
ful glucocorticoid response to LPS and proper clearance of LPS 
through the hepatocytes.
Sepsis is a complex process that can be divided into an early 
hyperinflammatory response stage that induces acute organ dys-
function and a later hypoinflammatory stage associated with 
immunosuppression (1). Treatment of sepsis is complicated, 
given the opposing natures of these 2 stages. Our findings suggest 
that SR-BI exerts protective functions throughout the process of 
sepsis, first by allowing a normal glucocorticoid response in the 
early hyperinflammatory stage and second, by limiting the LPS 
Table 2
Q-PCR primer sequences
Gene Accession Primers NT location 
 number  (size, bp)A
LDLR Z-19521 5′-AGGCTGTGGGCTCCATAGG-3′ 1181–1252
  5′-TGCGGTCCAGGGTCATCT-3′ (72)
HMG-CoA NM_008255 5′-CTTGTGGAATGCCTTGTGATTG-3′ 578–653
reductase  5′-AGCCGAAGCAGCACATGAT-3′ (76)
TNF-α NM_013693 5′-GGCAGGTCTACTTTGGAGTCATTG-3′ 833–970
  5′-GTTAGAAGGATACAGACTGG-3′ (138)
IL-6 NM_031168 5′-CAACGATGATGCACTTGCAG-3′ 265–400
  5′-GTAGCTATGGTACTCCAGAAG-3′ (136)
StAR NM_011485 5′-TTGGGCATACTCAACAACCA-3′ 312–414
  5′-GAAACACCTTGCCCACATCT-3′ (103)
CYP11A1 NM_019779 5′-CGAGACTTCAGCCAGTACCC-3′ 906–1003
  5′-GCCAGCATCTCGGTAATGTT-3′ (98)
ABCA1 NM_013454 5′-AGCCAGAAGGGAGTGTCAGA-3′ 2955–3056
  5′-CATGCCATCTCGGTAAACCT-3′ (102)
ANumbers without parentheses refer to primer location on the gene, while numbers within 
parentheses refer to PCR product size.
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burden during both stages by promoting LPS clearance. A recent 
study has reported that SR-BI protects against endotoxin-induced 
death by preventing NO-induced cytotoxicity (19). NO generation 
is induced during septic shock and contributes significantly to the 
symptoms of septic shock. Our results suggest that the glucocorti-
coid insufficiency seen in SR-BI–null mice might lead to enhanced 
endotoxic shock since glucocorticoids are known to inhibit NO 
production in a wide variety of cells (49). In the study by Li et al., 
however, NO levels in SR-BI–null mice were shown to be only 
moderately increased by LPS compared with control mice and the 
authors concluded that SR-BI prevents NO-induced cytotoxicity 
by mechanisms unrelated to NO synthesis (19).
Our data raise the possibility that the known protective role of 
SR-BI against atherosclerosis may be related to its antiinflam-
matory function. SR-BI–null mice and combined SR-BI/LDLR 
double-knockout mice on high-fat diets show accelerated ath-
erosclerotic lesion development compared with control mice (50, 
51). SR-BI/apoE–double-knockout mice not only develop athero-
sclerotic plaques but also have severe cardiac malfunction that 
includes spontaneous myocardial infarction and cardiac failure 
(52). Clearly, the lack of proper hepatic HDL cholesterol clear-
ance will have significant effects in these SR-BI–null models. 
Nevertheless, our findings suggest that an enhanced inflamma-
tory response may also contribute to atherogenesis in SR-BI–null 
mice. In SR-BI–null mice, for example, we show that chemokines 
produced in macrophages and vascular cells, such as MCP-1 and 
RANTES, are markedly upregulated during inflammation. These 
chemokines have been reported to promote the initiation of 
plaque formation (53, 54). Studies using these models will need 
to take cognizance of possible effects of altered adrenal function. 
Furthermore, SR-BI may also play important roles in the clear-
ance of endogenous proinflammatory reagents, including modi-
fied lipoproteins, such as oxidized LDL and other proinflamma-
tory lipids, and pathogens. In contrast, mice lacking the class B 
scavenger receptor CD36, which reportedly can also clear LPS in 
vitro (18), did not show the exaggerated inflammatory response 
to LPS seen in SR-BI–null mice. In fact, although CD36-null mac-
rophages showed a reduced cytokine response to LPS and E. coli 
challenge, CD36 deficiency in mice did not protect them from 
E. coli–induced lethality (55).
In summary, we demonstrate that SR-BI–mediated cholesterol 
delivery to the adrenals is essential for an effective antiinflamma-
tory glucocorticoid response to LPS or stress and SR-BI regulates 
LPS-induced inflammation and endotoxic shock. SR-BI serves a 
protective function in mediating LPS clearance from the plasma.
Methods
Animals and reagents. SR-BI–deficient mice (SR-BI null) were obtained from 
M. Krieger (Massachusetts Institute of Technology, Cambridge, Massachu-
setts, USA) (31). These mice lack both functional SR-BI and SR-BII. SR-BI 
homozygous (SR-BI–/–) mutant mice and control mice (both 1:1 mixed 
C57BL/6 × 129 backgrounds) were bred from 2 lines generated from a 
common mating pair of SR-BI heterozygous (SR-BI–/+) mice. Since female 
SR-BI–/– mice are infertile, SR-BI–/– mice were bred using SR-BI–/– male and 
SR-BI–/+ female mice. For all animal experiments, 8- to 12-week-old male 
and female mice, weighing 20–25 g, were used. All animal experiments were 
approved by the Veterans Affairs Medical Center, Institutional Animal Care 
and Use Committee.
LPS (E. coli serotype 0111:B4; 1 × 106 endotoxin units/mg LPS) was 
obtained from Sigma-Aldrich. Corticosterone and ACTH 125-I RIA assay 
kits were obtained from MP Biomedical. TNF-α and IL-6 ELISA kits were 
from R&D Systems, MCP-1 ELISA set was from BD Diagnostics, and the 
LAL assay kit was obtained from Cape Cod Inc.
E. coli (ATCC25922; ATCC) were cultured in Luria-Bertani broth and 
tryptic soy broth (ATCC) at 37°C using standard procedures and harvested 
at mid-log phase, which reached OD660= 5.0 (~2 × 108 CFUs/ml). Bacteria 
were washed twice, suspended in sterile saline, and injected i.p. into mice 
(2 × 107 CFUs E. coli/100 μl saline).
Corticosterone and ACTH determination. Plasma was isolated from blood 
obtained from SR-BI–null or control mice. Samples were assayed immedi-
ately to avoid degradation. Corticosterone levels and ACTH in the plasma 
were determined using specific radioimmunoassay kits (125I-RIA kit for 
ACTH and corticosterone; MP Biomedicals).
Cytokine determination. Serum was isolated from the blood of SR-BI–
null and control mice and immediately frozen at –80°C. Cytokine levels 
were determined by multiplex biomarker assay using xMAP technology 
by Linco Diagnostic Services Inc. Cytokine values were calculated using 
standard concentration curves determined for each cytokine on each 96-
well plate used. Plasma TNF-α levels and IL-6 levels were also determined 
using ELISA kits from R&D systems; MCP-1 was determined using ELISA 
sets from BD Diagnostics.
Q-PCR. Total RNA was isolated from mouse liver and adrenals using 
the standard TRIzol method (Invitrogen). RNA was further purified with 
DNase I (Roche) and RNeasy Mini Kit (QIAGEN). 2 μg of RNA was reverse 
transcribed into cDNA using a reverse-transcription system (Promega). 
After 4-fold dilution, 5 μl was used as a template for Q-PCR. Primers used 
in this study are listed in Table 2. Amplification was done for 40 cycles 
using Power SYBR Green PCR master Mix Kit (Applied Biosystem) and 
DNA Engine Optical 2 System (MJ Research Inc.). Both internal control 
(18S rRNA) and negative control (minus reverse transcriptase) were includ-
ed. Values of each RNA sample were the average of duplicate assays normal-
ized toward 18S rRNA (internal control) levels.
125I radioiodination and Alexa Fluor labeling of LPS. LPS was iodinated by the 
chloramine T method (56). In brief, 1 mg of LPS was dissolved in 0.05 M 
borate buffer (pH = 8) and incubated with 50 mM pOH methylbenzimi-
date at 37°C for 18 hours. After extensive dialysis, the M-LPS was radio-
labeled with Na125I by the chloramine T method. After iodination, the 
unincorporated Na125I was removed by extensive dialysis against sterile 
saline at 4°C. For fluorescent labeling of LPS, 1 mg of LPS was incubated 
with 1 vial of Alexa Fluor 488 dye (Invitrogen) in 0.1 M sodium borate 
buffer (pH = 10.5) for 3 hours at 37°C. After incubation, the mixture 
was dialyzed exhaustively against 4 liters of 150 mM NaCl with at least 
6 changes. The bioactivity of labeled LPS was determined by the LAL 
assay kit. Near-identical bioactivity was observed among unlabeled LPS, 
125-I-LPS, and Alexa Fluor–LPS.
LPS neutralization assay. Lipoproteins were preincubated with various 
amounts of LPS at 37°C for 1 hour, after which LAL activity of LPS 
was quantitatively determined according to the manufacturer’s instruc-
tions. The analytical sensitivity of the kit is 0.005 EU/ml (0.5 pg of 
highly purified LPS/ml).
Primary hepatocyte isolation and culture. The isolation of primary 
hepatocytes and nonhepatocytes was performed as described earlier (57) 
with certain modifications. In brief, livers were minced and dissociated in 
collagenase containing medium at 37°C for 10–12 minutes. Cell suspen-
sions were filtered through mesh (100 μm) and spun down. Hepatocytes 
were collected after a first spin (50 g for 2 minutes), while the nonhepato-
cytes were collected after a second spin (500 g for 10 minutes). Hepatocytes 
were washed twice in HBSS and suspended in enriched Williams’ E Medi-
um (GIBCO; Invitrogen). Viable cells were counted and plated in 24-well 
mouse collagen IV–coated plates (Fisher).
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LPS uptake into primary hepatocytes. Cell association assays were performed 
as described previously (13). In brief, primary hepatocytes were seeded into 
24-well cell culture clusters at an initial density of 1 × 105 cells/cm2. When 
cells reached confluency, they were washed with phosphate-buffered saline 
and incubated at 37°C for 2 hours with 125I-LPS in DMEM medium con-
taining 0.5% essentially fatty acid free albumin (BSA). After incubation, 
medium was removed and the cells were washed 4 times with cold buffer 
(50 mM Tris-HCl, 150 mM NaCl, pH 7.4) containing BSA (2 mg/ml) fol-
lowed by 2 washes in the same buffer without BSA. The cells were then 
solubilized in 0.1 N NaOH for 1 hour at room temperature, and the pro-
tein and 125I content of the lysate were determined.
Adrenalectomy. SR-BI–null and control mice were adrenalectomized fol-
lowing standard surgical procedures (58). Following surgery, mice were 
placed in individual clean cages and allowed to recover for 1 week while 
maintained on normal chow diet and drinking water containing 0.9% sodi-
um chloride. Sham-operated control mice underwent the same surgical 
procedure as adrenalectomized groups, except their adrenal glands were 
not excised. Experiments were performed 1 week after surgery. Sham-oper-
ated and test mice were injected i.p. with LPS and sacrificed 2 hours later.
Survival determination. SR-BI–/– mice, SR-BI+/– mice, and SR-BI+/+ mice 
were injected i.p. with 5 μg/g body weight of LPS. In some experiments, 
SR-BI–/– mice were given corticosterone (Sigma-Aldrich), initially dissolved 
in ethanol, in their drinking water (100 μg/ml) starting 8 hours prior to 
LPS injection. In these experiments, control groups were given an equiva-
lent amount of vehicle only (0.1% ethanol) in their drinking water. Mice 
were allowed to eat and drink freely. Mice were under careful observation 
for behavior and survival during the following 3 days.
Swim stress test and ACTH treatment. For the stress test, female mice were 
placed in 5°C water and forced to swim for 3 minutes (59). Following the 
swim, mice were rested at room temperature for 17 minutes prior to sac-
rifice. Blood was taken for corticosterone and ACTH determination. For 
ACTH treatment, mice were s.c. injected with the indicated amounts of 
ACTH (Questcor Pharmaceutical).
LPS clearance. SR-BI–null mice and control mice (n = 4) were injected with 
0.125 μg/g body weight of 125 I-LPS through tail veins. Mice were sacrificed 
after 30 minutes, and blood and tissue were collected for analysis. Plasma 
and tissue samples were weighed and counted in a γ counter (Packard; 
PerkinElmer Life Inc). Tissue uptake was determined as described (3).
Statistics. Statistical comparison between control and the SR-BI–null animals 
within the same treatment group and between different treatment groups 
within the same genotype were carried out in each experiment, and all signifi-
cant differences (P < 0.05) are given in the figures and/or figure legends. Sta-
tistical significance in experiments comparing only 2 groups was determined 
by 2-tailed Student’s t test. The significance of the difference in mean values 
among more than 2 groups was evaluated by 1-way ANOVA, followed by post 
hoc analysis using Tukey’s test. To determine statistical significance between 
survival curves, Kaplan-Meier log-rank test was used. All statistical analyses 
were done with GraphPad Prism 4 (GraphPad Software). Values are expressed 
as mean ± SD. A P value of less than 0.05 was considered significant.
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